Lilly to Present New Data for Taltz ixekizumab in Psoriasis and Psoriatic Arthritis at the American Academy of Dermatology AAD Annual Meeting

INDIANAPOLIS Feb. 28 2017 PRNewswire Eli Lilly and Company NYSE LLY will highlight new Phase 3 data evaluating Taltz ixekizumab for the treatment of moderatetosevere plaque psoriasis and active psoriatic arthritis at the 75th annual meeting of the Americ...